GlassScriptPhysician profile
David S Peterson
NPI 1801968359
$3,258.47
in general payments reported to CMS, 2019-2025
32 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $396 · 2021: $341 · 2022: $701 · 2023: $560 · 2024: $794 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.68 |
| Education | $134.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $497.98 | 2020-2025 | Mavenclad |
| Harmony Biosciences LLC | $353.93 | 2020-2025 | Wakix |
| Abbvie INC. | $305.70 | 2021-2025 | |
| Lundbeck LLC | $202.19 | 2022-2025 | Vyepti |
| Ucb, INC. | $191.44 | 2019-2024 | Fintepla |
| Novartis Pharmaceuticals Corporation | $172.64 | 2019-2024 | |
| Celgene Corporation | $170.47 | 2021-2025 | Zeposia |
| Avadel Cns Pharmaceuticals, LLC | $142.30 | 2023-2025 | Lumryz |
| Argenx US, INC. | $141.13 | 2023-2025 | Vyvgart Hytrulo |
| Axsome Therapeutics, INC. | $120.18 | 2024-2025 | Sunosi, Symbravo |
| Teva Pharmaceuticals USA, INC. | $103.54 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $98.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.52 | 2023-2024 | Hyqvia |
| Biogen, INC. | $66.89 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $65.64 | 2020-2024 | Ingrezza |
| Impel Pharmaceuticals INC. | $61.63 | 2022-2023 | Trudhesa |
| Amneal Pharmaceuticals LLC | $55.63 | 2022-2023 | Rytary |
| Pfizer INC. | $54.70 | 2023-2024 | |
| Arbor Pharmaceuticals, INC. | $45.95 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $43.49 | 2020-2021 | |
| Amgen INC. | $28.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.84 | 2022 | |
| Allergan, INC. | $24.32 | 2020 | |
| Acadia Pharmaceuticals INC | $23.06 | 2021 | |
| Avanir Pharmaceuticals, INC. | $19.26 | 2019 | |
| Inspire Medical Systems, INC. | $15.33 | 2024 | Inspire |
| Upsher-Smith Laboratories LLC | $15.16 | 2020 | |
| Tanabe Pharma America, INC. | $13.93 | 2023 | |
| Genzyme Corporation | $13.58 | 2021 | |
| Banner Life Sciences, LLC | $13.30 | 2022 | |
| Philips North America LLC | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.